Red Flags Detected

• ⚠ 7,209,333 Common Shares Issuable Upon the Exercise of Outstanding Warrants, At a Weighted Average Exercise Price of $19.05 (new) — A large warrant overhang exists with exercise prices far above the current offer price, creating potential future dilution if the stock appreciates.
• ⚠ On July 3, 2024, the Company Received a Letter From the Listing Qualifications Department of Nasdaq Indicating That... the Company Did Not Meet the Minimum Mvls of $35,000,000... (new) — The company has a history of Nasdaq listing non-compliance, indicating ongoing listing risk that could affect liquidity and financing.
• ⚠ We Are Substantially Dependent On the Success of Our Lead Product Candidate and Our Related Pipeline Candidates (new) — The company's business is highly concentrated on a single lead product candidate, making it vulnerable to clinical or regulatory setbacks.